Physician profile
Joy Broyles
NPI 1679877328
$7,604.85
in general payments reported to CMS, 2019-2025
49 companies · $3,322 in 2025
The $3,322 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $485 · 2022: $670 · 2023: $1,750 · 2024: $1,378 · 2025: $3,322.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,291 · Education: $159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,290.89 |
| Education | $158.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $619.11 | 2022-2025 | Enhertu, Datroway |
| Janssen Biotech, INC. | $477.97 | 2022-2025 | Rybrevant, Erleada, Carvykti |
| Merck Sharp & Dohme LLC | $415.31 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Seagen INC. | $406.57 | 2021-2023 | Adcetris, Padcev, Tukysa |
| E.R. Squibb & Sons, L.L.C. | $394.57 | 2022-2025 | Reblozyl, Opdivo, Onureg |
| Abbvie INC. | $389.72 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $379.71 | 2021-2025 | |
| Genzyme Corporation | $371.14 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $338.01 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $332.65 | 2021-2025 | Enhertu, Lynparza |
| Takeda Pharmaceuticals U.S.A., INC. | $305.39 | 2022-2025 | Fruzaqla, Iclusig, Ninlaro |
| Puma Biotechnology, INC. | $291.38 | 2023-2025 | |
| Incyte Corporation | $246.74 | 2021-2025 | Monjuvi, Zynyz, Jakafi |
| Pfizer INC. | $239.93 | 2023-2025 | |
| Lilly USA, LLC | $196.32 | 2023-2025 | Jaypirca, Verzenio, Retevmo |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $189.00 | 2023-2025 | Ojjaara, Jemperli, Zejula |
| Astellas Pharma US INC | $187.90 | 2025 | Padcev, Xtandi |
| Beone Medicines USA, INC. | $129.13 | 2025 | Tevimbra, Brukinsa |
| Myriad Genetic Laboratories, INC. | $128.90 | 2025 | Myrisk |
| Pharmacosmos Therapeutics INC. | $126.97 | 2024-2025 | Monoferric |
| Beigene USA, INC. | $116.36 | 2023-2025 | Brukinsa, Tevimbra |
| Sobi, INC | $107.93 | 2022-2025 | |
| Genentech USA, INC. | $105.86 | 2021-2025 | Phesgo, Perjeta, Tecentriq |
| Gilead Sciences, INC. | $103.39 | 2022-2025 | Trodelvy |
| Eisai INC. | $99.26 | 2023-2024 | |
| Alexion Pharmaceuticals, INC. | $95.02 | 2023-2025 | Ultomiris |
| Adc Therapeutics America, INC. | $90.76 | 2024-2025 | |
| Celgene Corporation | $85.92 | 2021-2025 | Reblozyl, Opdualag |
| Sanofi-Aventis U.S. LLC | $81.00 | 2025 | |
| Mirati Therapeutics, INC. | $58.24 | 2023-2024 | Krazati |
| Sirtex Medical INC | $55.64 | 2024 | Sir-Spheres Microspheres |
| Stemline Therapeutics INC. | $55.16 | 2023-2024 | Orserdu |
| Deciphera Pharmaceuticals INC. | $44.73 | 2021-2025 | Romvimza, Qinlock |
| Blueprint Medicines Corporation | $43.85 | 2021-2022 | |
| Aveo Pharmaceuticals, INC. | $24.77 | 2022 | |
| Janssen Pharmaceuticals, INC | $23.79 | 2025 | Erleada |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.67 | 2023 | Gilotrif |
| Ipsen Biopharmaceuticals, INC | $22.48 | 2024 | Tazverik |
| Caris Mpi, INC. | $22.36 | 2025 | Mi Cancer Seek |
| Pharmacyclics LLC, An Abbvie Company | $20.83 | 2022 | |
| Immunogen, INC. | $20.56 | 2023 | Elahere |
| Agios Pharmaceuticals, INC. | $19.72 | 2023 | Pyrukynd |
| Jazz Pharmaceuticals INC. | $19.10 | 2021 | |
| Karyopharm Therapeutics INC. | $18.98 | 2022 | |
| Amgen INC. | $18.87 | 2021 | |
| Eusa Pharma (US) LLC | $18.21 | 2021 | |
| Myovant Sciences INC. | $15.87 | 2021 | |
| Novocure INC. | $14.74 | 2025 | Optune Lua (Novottf-200t) |
| Helsinn Therapeutics (U.S.), INC. | $12.36 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joy Broyles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.